...
首页> 外文期刊>Annals of epidemiology >Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: A pharmacovigilance analysis
【24h】

Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: A pharmacovigilance analysis

机译:与暴露于全身氟喹诺酮类药物的外周神经病变和Guillain-Barré综合征风险:药物检测分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: Peripheral neuropathy (PN) is an identified risk of systemic antibacterial therapy with fluoroquinolones. The risk and its severity, including the development of Guillain-Barré syndrome (GBS) between individual agents is uncertain. This study examines the association between fluoroquinolones and PN and GBS in cases spontaneously reported to the FDA Adverse Event Reporting System. Methods: Cases reported to FDA Adverse Event Reporting System between 1997 and 2012 were retrieved. The Medical Dictionary for Regulatory Activities Preferred Term was used to define PN and GBS. Individual fluoroquinolones were identified by generic names and route of administration. Empirical Bayes Geometric Mean (EBGM) with 95% confidence interval (EB05-EB95) was calculated as disproportionality measure. Safety signals with EB05 2 or more was considered a significant disproportional increase in the event reporting of at least twice times higher than that expected. Results: There were 539 PN reports out of 46,257 adverse event reports submitted for fluoroquinolones. Nine percent of PN reports were for GBS. Significant disproportionality of PN (EBGM 2.70; EB05-EB95 2.51-2.90) and GBS (EBGM 3.22; EB05-EB95 2.55-4.02) was identified for fluoroquinolones. Signals of PN were detected for ciprofloxacin (EBGM 3.24; EB05-EB95 2.87-3.66) and levofloxacin (EBGM 3.36; EB05-EB95 3.02-3.72). A GBS signal was detected for ciprofloxacin (EBGM 4.15; EB05-EB95 2.94-5.74). GBS and PN, respectively, ranked 6th and 8th among reported neurologic events. Conclusions: This study re-emphasizes the link between fluoroquinolones and PN and shows the potential association with more severe forms of nerve damage, for example, GBS. Unless the benefit of fluoroquinolone therapy (e.g., overwhelming infection or development of bacterial resistance) outweighs PN risk, treatment with alternative antibacterial agents is recommended.
机译:目的:外周神经病变(PN)是氟喹诺酮类药物鉴定的全身抗菌治疗的风险。风险及其严重程度,包括在各个代理之间的突厥屠杀综合征(GBS)的发展是不确定的。本研究检测FDA不良事件报告系统自发地报告的含氟喹啉酮和PN和GBS之间的关联。方法:退回了1997年至2012年间FDA不良事件报告系统的案件。用于监管活动的医学词典优选术语用于定义PN和GBS。通过通用名称和给药途径鉴定单个氟喹啉酮。具有95%置信区间(EB05-EB95)的经验贝叶斯几何平均值(EBGM)被计算为不成比例测量。使用EB05 2或更多的安全信号被认为是比预期的至少两次的事件报告的显着解体增加。结果:为氟代喹啉雄素提交的46,257个不良事件报告中有539 PN报告。百分之九的PN报告是GBS。对于氟代喹啉酮鉴定出氟化喹啉的Pn(EBGM 2.70; EB05-EB95 2.51-2.90)和GBS(EBGM 3.22; EB05-EB95 2.55-4.02)的显着不成比例。检测PN的信号,用于CiProfloxacin(EBGM 3.24; EB05-EB95 2.87-3.66)和左氧氟沙星(EBGM 3.36; EB05-EB95 3.02-3.72)。检测到环丙沙星(EBGM 4.15; EB05-EB95 2.94-5.74)检测到GBS信号。 GBS和PN分别在报告的神经系统事件中排名第6和第8位。结论:本研究重新强调氟代喹啉和Pn之间的联系,并显示出与更严重的神经损伤形式的潜在关联,例如GB。除非氟代喹啉酮治疗的益处(例如,压倒性感染或细菌抗性的发育)超过PN风险,建议使用替代抗菌剂的处理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号